Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Acronyms CAPSIL
- 16 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2016 Planned End Date changed from 1 Feb 2017 to 1 Sep 2018.
- 24 Oct 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Jun 2018.